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Abstract: The role of granulocyte-macrophage-colony-stimulating factor (GM-CSF) in the 
supportive care of cancer patients has been evaluated with promising results. More recently, 
GM-CSF has been added to regimens for the mobilization of hematopoietic progenitor cells. 
An expanding role for GM-CSF in regulating immune responses has been recognized based 
upon its activity on the development and maturation of antigen presenting cells and its capa-
bility for skewing the immune system toward Th1-type responses. GM-CSF has been shown 
to preferentially enhance both the numbers and activity of type 1 dendritic cells (DC1), the 
subsets of dendritic cells responsible for initiating cytotoxic immune responses. The increase 
in DC1 content and activity following local and systemic GM-CSF administration support a 
role for GM-CSF as an immune stimulant and vaccine adjuvant in cancer patients. GM-CSF 
has shown clinical activity as an immune stimulant in tumor cell and dendritic cell vaccines, 
and may increase antibody-dependent cellular cytotoxicity. The successful use of myeloid act-
ing cytokines to enhance anti-tumor responses will likely require the utilization of GM-CSF in 
combination with cytotoxic or other targeted therapies.
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Introduction/background
Granulocyte-macrophage-colony-stimulating factor (GM-CSF) and granulocyte-
colony-stimulating factor (G-CSF) belong to the family of hematopoietic cyto-
kines. Their activities include stimulating the proliferation of granulocyte and/or 
macrophage progenitor cells, inﬂ  uencing differentiation, inducing maturation, and 
stimulating the functional activity of mature hematopoietic cells (Inaba et al 1992; 
Metcalf and Nicola 1995; Metcalf 1998). Colony stimulating factors (CSF) are not 
only important as mediators of the cellular response to immunologic or infectious 
insults but are also essential for maintaining basal hematopoiesis (Dranoff et al 
1994; Fantuzzi 2003). G-CSF-deﬁ  cient mice manifest a chronic neutropenia and 
an impaired response to infectious challenge leading to premature death (Lieschke 
et al 1994). GM-CSF-deﬁ  cient mice, on the other hand, have normal levels of 
steady-state blood cell production, but exhibit defective phagocytosis and decreased 
oxygen radical production by granulocytes and macrophages; responses which are 
essential for the anti-bacterial defense (Stanley et al 1994; Zhan et al 1998; LeVine 
et al 1999). These mice also exhibit decreased tumor necrosis factor-alpha and 
leukotriene secretion, abnormal para-bronchial accumulations of B and T lympho-
cytes, and decreased catabolism of alveolar surfactant lipids and proteins leading 
to a syndrome reminiscent of pulmonary alveolar proteinosis (Stanley et al 1994; 
Paine et al 2001). Double G-CSF and GM-CSF knockout mice exhibited a greater 
degree of neutropenia, and had an increased mortality rate in the early post-natal 
period compared to mice deﬁ  cient in G-CSF alone (Seymour et al 1997). Enzler 
et al (2003) found that mice deﬁ  cient in GM-CSF and gamma interferon (IFN-γ) Biologics: Targets & Therapy 2008:2(1) 14
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acquired lymphoproliferative disorders and solid tumors 
in a background of chronic inﬂ  ammation, supporting the 
relationship between inﬂ  ammation and carcinogenesis.
Recombinant GM-CSF has made signiﬁ  cant contribu-
tions in the supportive care of cancer patients, owing to 
enhanced myeloid recovery after cytotoxic chemotherapy. 
Recently GM-CSF has been successfully included in mobi-
lization regimens for hematopoietic progenitor cell trans-
plantation (Cashen et al 2004; Lonial et al 2004). Recent 
data on the effects of GM-CSF on dendritic cells has led 
to growing interest in its use as primary immunotherapy. 
The ability of GM-CSF to generate of type 1 dendritic cells 
(DC1), which can skew T-cells toward a Th-1 phenotype 
has been demonstrated and is an attractive approach toward 
generating anti-tumor effects (Ferlazzo et al 2000). Periph-
eral blood mononuclear cells (PBMC), T-cells and antigen 
presenting cells (APC) cultured with GM-CSF exhibited 
increased production of type 1 cytokines (interleukin-12, 
interferon-alpha, tumor necrosis factor-alpha) and decreased 
production of type 2 cytokines (interleukin-4 and interleu-
kin-10) compared to cells treated with control media or 
G-CSF (Eksioglu et al 2007). In addition, APC treated with 
GM-CSF induced higher proliferation of allogeneic T-cells 
compared to APC treated with G-CSF or control media 
(Eksioglu et al 2007). The capacity of GM-CSF to skew the 
immune system toward Th1 effects in vitro suggests a role 
for GM-CSF in cell-mediated immune therapy and is cur-
rently being tested in-vivo. Dendritic cells (DC) have come 
to be recognized as the sensors of tissue injury, infection, 
or malignant transformation and as the agents responsible 
for the initial activation of the immune response (Matzinger 
1994). DC are the antigen presenting cells of the immune 
system, have the capacity to express both HLA class I and 
HLA class II restricted peptides, and express the co-stimula-
tory molecules needed for T-cell activation (Banchereau et al 
2000). A number of reports have shown that administration 
of GM-CSF can induce anti-tumor immune responses and 
tumor regressions. These immune activities are attributed 
to the action of GM-CSF on DC (Dranoff et al 1993; Wos 
et al 1996; Davidson et al 1998). The limitations of GM-CSF 
as an immune adjuvant, and its modest clinical activity, 
have been attributed to discordance between the observed 
immune response measured in the laboratory and the clinical 
correlates of anti-tumor activity. The need to generate the co-
stimulatory signals required to break immune tolerance, the 
proper dosing and timing of cytokines, the state of disease at 
time of treatment, and the role of concomitant chemotherapy 
are the topics of current investigation. In this review, we will 
discuss the role of GM-CSF as primary treatment and as an 
immune adjunct to the therapy of cancer.
Relationship between cancer 
and inﬂ  ammation
The connection between inflammation and malignant 
transformation has been recognized for over a century. In 
1863, Dr. Rudolf Virchow recognized a possible relation-
ship between chronic inﬂ  ammation and the development of 
cancer, based on observations of inﬂ  ammatory inﬁ  ltrates and 
spontaneous regression of malignant tumors (Balkwill and 
Mantovani 2001; Schreiber 2003). In the late 1890s, William 
Coley, a surgeon in New York, observed tumor regressions 
in patients with cancer who recovered from acute skin infec-
tions. He then developed a vaccine composed of extracts of 
inactivated bacteria, which he administered to cancer patients 
with variable results (Nauts et al 1953). He observed that 
tumor regressions were more common among patients who 
developed both a local and a systemic inﬂ  ammatory response 
(Hoption Cann et al 2002). The premise was that non-speciﬁ  c 
activation of the immune system could lead to (speciﬁ  c) 
cytokine-mediated anti-tumor effects. While cytokines are 
credited with potent anti-tumor effects, a counteracting effect 
of tumor-secreted cytokines, and tumor-associated tolerizing 
T-cells, or immature DC has also been documented (Perrot 
et al 2007; Wang and Wang 2007). Some solid tumors, for 
example, are capable of inducing immune tolerance via 
down-regulation of antigen-speciﬁ  c T-cell responses by 
tolerigenic APC (Cuenca et al 2003). Immature tumor-inﬁ  l-
trating DC are capable of compromising the tumor-speciﬁ  c 
immune response in draining lymph nodes (Perrot et al 2007). 
The premise that the immune system can be manipulated in 
vivo supports a role for the manipulation of the cytokine/co-
stimulatory signal milieu in the treatment of cancer using 
recombinant cytokines, such as GM-CSF.
Approaches will need to account 
for the level of maturation of tumor-
associated DC, and the number 
of tumor-associated regulatory T-cells
GM-CSF may enhance tumor-speciﬁ  c antigen presenta-
tion leading to better recognition of tumors by the immune 
system via effects on DC. However, its beneﬁ  t has been 
limited to patients with minimal residual disease, and dose-
escalation has been limited by signiﬁ  cant systemic toxici-
ties. The optimal use of cytokines may be directly in the 
tumor micro-environment. Furthermore, better quantitative Biologics: Targets & Therapy 2008:2(1) 15
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measures of antigen-speciﬁ  c immune responses are needed 
(Keilholz et al 2002).
Role of GM-CSF in supportive 
therapy
Numerous clinical trials have established the role of CSF in 
the prevention and treatment of febrile neutropenia (Garcia-
Carbonero et al 2001; Mizutani et al 2003; Repetto et al 2003). 
The majority of clinical trials investigated the role of G-CSF 
in the supportive care of cancer patients; therefore, the current 
recommendations do not address the speciﬁ  c use of GM-CSF 
in this setting. The American Society of Clinical Oncology 
(ASCO) has provided guidelines for the use of CSF (either 
G-CSF or GM-CSF) in patients receiving chemotherapy for 
solid and hematological malignancies (Smith et al 2006). 
No recommendation was made regarding the equivalency of 
G-CSF and GM-CSF. Rowe et al reported a signiﬁ  cant reduc-
tion of infectious complications in patients with acute myeloid 
leukemia (AML) who received GM-CSF after induction che-
motherapy, compared to placebo (Rowe et al 1995). However, 
Zittoun et al (2006) reported a decreased complete response 
(CR) rate in patients with AML who received GM-CSF with 
induction chemotherapy, indicating that the routine use of 
cytokines for acceleration of hematopoietic recovery may 
not always be indicated; and the use of CSF for priming of 
leukemic cells is not recommended.
Dendritic cells as regulators 
of immune responses
DC play a central role in the initiation of innate and adaptive 
immune responses. Pattern recognition receptors, known as 
toll-like receptors (TLR), on the surface of DC are bound by 
proteins, lipids, and nucleic acids resulting in DC activation 
(Kadowaki et al 2001; Dillon et al 2004). Antigen-speciﬁ  c 
T-cell immune responses are initiated by DC when these 
bound antigens are internalized, degraded, and presented as 
processed peptides on the surface of HLA molecules (Hart 
1997; Bancereau and Steinman 1998; Banchereau et al 2000). 
Two main categories of peripheral blood and bone marrow 
derived DC have been described in humans, type 1, myeloid 
dendritic cells (DC1), and type 2 plasmacytoid dendritic cells 
(DC2) (Grouard et al 1997). DC1 and DC2 differ in the type 
of cell differentiation markers and TLR expressed on their 
surface, their cytokine milieu, and their effect on polarizing 
T-cell immune responses (Rissoan et al 1999; Amsen et al 
2004; Dillon et al 2004). The maturation status of DC is an 
important determinant of the type of immune response gener-
ated upon DC activation. For example, antigen presentation 
by immature DC leads to generation of anergic CD4+ T-cells 
(Kuwana et al 2001), and immuno-suppressive CD8+ T-cells 
with antigen-speciﬁ  city (Gilliet and Liu 2002). Immature DC2 
progenitors play a crucial role in the response to viral infection 
by releasing large amounts of alpha and beta interferon (Siegal 
et al 1999; Fonteneau et al 2003; Larsson et al 2003; Coccia 
et al 2004). The targeting of DC by synthetic TLR ligands is 
a topic of current clinical and pre-clinical research.
Generation of dendritic 
cells by GM-CSF
Colony-stimulating factors can differentiate hematopoietic 
progenitor cells into speciﬁ  c DC lineages (Santiago-Schwarz 
et al 1992; Grouard et al 1997; Olweus et al 1997; Rissoan 
et al 1999; Siegal et al 1999; Berthier et al 2000; Ferlazzo et al 
2000). Hematopoietic stem cells cultured in GM-CSF and 
Flt3 can differentiate along a myelo-monocytic lineage into 
DC1 (Ferlazzo et al 2000). CD14+ progenitor cells cultured 
in GM-CSF and IL-4 can also differentiate into immature 
DC1 (Ferlazzo et al 2000; Basak et al 2002). In contrast, treat-
ment of hematopoietic progenitors with G-CSF and IL-3 can 
mobilize large numbers of (plasmacytoid) DC2 (Arpinati et al 
2000). Thus, while GM-CSF and G-CSF have similar effects 
on the mobilization of neutrophils, they have signiﬁ  cantly dif-
ferent effects on the mobilization and differentiation of DC1 
and DC2, with culture in GM-CSF leading to differentiation 
of progenitors into DC1, and culture in G-CSF leading to 
differentiation of progenitors into DC2 (Arpinati et al 2000). 
Due to their effects on DC1 and DC2, these 2 cytokines are 
optimal agents for cellular immune therapy.
Cytokines and peripheral blood 
hematopoietic progenitor cell 
transplantation
Peripheral blood as a source of stem cells for clinical stem 
cell transplantation was introduced by Korbling et al and 
Kessinger et al in the 1980s (Korbling et al 1981; Kessinger 
et al 1986). CSF are now widely used for the mobilization 
of hematopoietic progenitor cells into the peripheral circula-
tion, allowing collection of CD34+ cells for autologous and 
allogeneic hematopoietic progenitor cell transplantation. 
Essential differences have been noted between bone marrow 
(BMT) and peripheral blood grafts, owing to differences in the 
ratio of early pluripotent, self-renewing stem cells to lineage-
committed, late progenitor cells, and the accessory cells in the 
grafts (Korbling and Anderlini 2001). These differences may 
account for the observed differences in clinical outcomes after Biologics: Targets & Therapy 2008:2(1) 16
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transplantation. A study by the European working group for 
blood and marrow transplant reported similar rates of overall 
survival, leukemia-free survival, and similar incidence of graft 
versus host disease (GVHD) when comparing bone marrow 
with cytokine-mobilized peripheral blood grafts. They did, 
however, observe improved platelet recovery with cytokine-
mobilized peripheral graft compared to BMT (Schmitz et al 
1998). A randomized, multi-center trial of cytokine-mobilized 
peripheral blood progenitor cell grafts versus BMT reported 
by Schmitz et al (2002), found an increased risk of acute 
and chronic GVHD among recipients of cytokine-mobilized 
peripheral blood grafts, but no difference in survival compared 
to recipients of bone marrow transplants. In contrast, in another 
randomized trial comparing peripheral blood hematopoietic 
progenitor cell and bone marrow transplantation, Bensinger 
et al found more rapid neutrophil and platelet recovery and 
similar rates of acute and chronic GVHD. In that trial, the 
duration of chronic GVDH was longer among recipients of 
blood progenitor cell grafts. Furthermore, recipients of blood 
progenitor cell grafts had a higher estimated probability of 
overall survival and 2-year disease-free survival (Bensinger 
et al 2001). Interestingly, Urbini and colleagues found a higher 
number of CD34+ cells in peripheral blood grafts mobilized 
with G-CSF compared to bone marrow, and the dose of CD34+ 
cells infused correlated with the number of DC1 in peripheral 
blood grafts and DC2 in bone marrow allografts. In addition, 
among recipients of cytokine mobilized grafts, a signiﬁ  cantly 
shorter overall survival and a trend toward lower disease free 
survival was noted among recipients of larger numbers of 
CD34+ cells (Urbini et al 2003).
The fact that the incidence of acute GVHD in recipients 
of peripheral blood progenitor cell grafts was similar to, or 
only slightly higher than in BMT recipients, despite the higher 
content of T cells in the peripheral blood grafts, suggests that 
there may be quantitative differences in the other immune 
cellular components of peripheral blood grafts; such as, the 
presence of increased numbers of immunosuppressive DC2 
in G-CSF mobilized peripheral blood grafts compared to 
bone marrow grafts (Arpinati et al 2000).
Clinical outcomes after 
hematopoietic progenitor cell 
transplantation: contribution 
of dendritic cells
Recent growing interest in the role of accessory cells in 
hematopoietic progenitor cell grafts has led to further 
studies of the immune-modulatory effects of CSF on the 
constituents of the peripheral blood progenitor cell graft. 
Flt3 and GM-CSF administration led to mobilization of 
increased numbers of DC1 in the cellular apheresis product 
(Gasparetto et al 2002). In contrast, administration of G-CSF 
lead to mobilization of increased numbers of DC2 cells in 
the grafts (Arpinati et al 2000). The clinical consequences 
of mobilizing more DC1 with GM-CSF and more DC2 
with G-CSF remain unknown, and are the subject of current 
investigation.
Waller et al tested the hypothesis that the cellular con-
stituents of the graft could affect clinical outcomes after bone 
marrow transplantation (Waller et al 2001). They performed 
a retrospective study of 113 patients with hematological 
malignancies who received non-T cell-depleted bone marrow 
grafts from HLA-matched siblings. After evaluating patient 
and disease-speciﬁ  c characteristics, characteristics of the 
graft constituents, and clinical outcomes, they reported that 
patients who received larger numbers of donor DC2 had 
signiﬁ  cantly worse clinical outcomes, with lower event-free 
survival, less chronic GVHD, and an increased incidence of 
relapse than their counterparts who received fewer numbers 
of DC2 cells (Waller et al 2001).
The signiﬁ  cance of absolute numbers of DC in post-
transplant outcomes was also evaluated in a clinical study 
by Reddy and colleagues (Reddy et al 2004). Fifty patients 
undergoing allogeneic transplantation for hematological 
disorders were evaluated. After evaluating the constituents 
of the grafts, as well as the type and number of DC in the 
peripheral blood early after engraftment, they noted that 
patients with lower absolute numbers of DC ( 4.97 cells/μL) 
at engraftment had worse clinical outcomes compared to 
patients with higher numbers of DC at engraftment, with 
lower overall survival (p = 0.002), increased incidence of 
relapse (p = 0.002), and a higher incidence of acute GVHD 
(p = 0.0005). Multivariable analysis conﬁ  rmed that low DC 
count was independently associated with death (hazard ratio 
[HR], 3.8; p = 0.02), time to relapse (HR, 11.6; p = 0.001), 
and acute GVHD (HR, 3.3; p = 0.04). The effect was similar 
when DC1 were analyzed separately. However, when DC2 
were analyzed separately, the effect was only signiﬁ  cant for 
increased incidence of acute GVHD among patients with 
lower numbers of DC2 at engraftment. The independent 
effect of DC1 and DC2 was not conﬁ  rmed in the multivariate 
analysis (Reddy et al 2004).
Subsequently, Lonial and colleagues hypothesized that 
the combination of G-CSF and GM-CSF administered for the 
mobilization of stem cells after chemotherapy would reduce 
the content of DC2 in the autologous blood hematopoietic Biologics: Targets & Therapy 2008:2(1) 17
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progenitor cell grafts compared with administration of G-CSF 
alone after chemotherapy (Lonial et al 2004). They random-
ized 35 patients with lymphoma and multiple myeloma to 
receive either G-CSF or the combination of G-CSF plus 
GM-CSF after chemotherapy. Blood hematopoietic progeni-
tor cell grafts were collected by large volume apheresis. They 
found a similar incidence of cytokine-related adverse events, 
and similar numbers of stem cells mobilized between the 2 
treatment groups. There were minor differences with respect 
to the content of T cells in the apheresis products. However, 
grafts mobilized with the combination of GM-CSF plus 
G-CSF had signiﬁ  cantly fewer DC2 and similar numbers of 
DC1 compared with grafts mobilized with G-CSF alone. A 
third cohort of patients received G-CSF and the sequential 
administration of GM-CSF 6 days later. Grafts from these 
patients had a markedly decreased DC2 content compared 
with grafts mobilized from patients treated with G-CSF alone 
or with the simultaneous administration of both cytokines. 
This preliminary trial formed the foundation for a randomized 
clinical trial where normal volunteer donors were randomized 
to receive either G-CSF or G-CSF plus GM-CSF in order to 
evaluate the impact of these cytokines on DC content, T-cell 
polarization, and immune function after allogeneic transplan-
tation. Fifty patients were enrolled in the trial with 25 in the 
GM+G-CSF and 25 in the G-CSF alone arm. All patients 
were successfully mobilized. Among donors mobilized 
with G-CSF alone, the mean number of collections was 1.48 
compared with 1.08 in the group receiving the combination 
of GM+G-CSF (p = 0.01). There was a trend toward a higher 
total cell dose in the G-CSF arm (p = 0.09). Two of the 25 
donors in the G/GM group required more than 1 apheresis, 
and 8 of 25 donors in the G-CSF alone group required more 
than 1 collection to achieve an adequate number of CD34+ 
cells. Analysis of the T-cell and T-cell subset data revealed 
that in the group receiving G-CSF alone, there was a signiﬁ  -
cantly higher percent and total T-cell, CD4+ and CD8+ cell 
content of the grafts when compared with the group receiving 
the GM+G-CSF combination. Among dendritic cell subsets 
in the grafts, there was a signiﬁ  cantly lower percentage and 
fewer absolute numbers of DC2, as well as a lower delivered 
DC2 dose/kg for the group randomized to receive GM-CSF 
plus G-CSF compared with the group randomized to receive 
G-CSF alone (p   0.001). There was no signiﬁ  cant difference 
in the DC1 content or the content of CD34+ cells between 
the 2 treatment arms. Proliferation of the graft in response 
to T and B-cell mitogens was measured on the graft itself. 
Cells were exposed to mitogens or control for 72 hours, and 
then thymidine incorporation was measured. So far, there 
are available data on mitogen stimulation for 32 patients, 
showing a trend toward more IL-12 secretion for G+GM-CSF 
mobilized grafts, and more IL-2 secretion for G-CSF mobi-
lized grafts. There have been no differences in the incidence 
of GvHD, relapse or survival between the 2 cytokine arms 
to date (Lonial et al 2004; Lonial et al 2006).
These data, and data indicating that cross-presentation 
of antigen by DC2 may induce antigen-speciﬁ  c tolerance by 
T cells, suggest that the addition of GM-CSF to regimens 
during mobilization of peripheral blood progenitor cell grafts 
may be a clinically applicable strategy to enhance innate 
and acquired immunity after peripheral blood progenitor 
cell transplantation (Kuwana et al 2001; Gilliet and Liu 
2002). Larger clinical trials are needed to determine the 
exact consequences of altering the DC1 and DC2 content of 
peripheral blood hematopoietic progenitor cell grafts. Those 
effects may include: incidence of acute and chronic GVHD, 
engraftment, graft rejection, graft versus leukemia effect and 
response to infection.
Role of GM-CSF in post transplant 
immune reconstitution
Recent data on the differential effects of GM-CSF and G-CSF 
on the DC subsets in the graft, has inspired clinical studies 
to investigate whether the administration of these cytokines 
following autologous hematopoietic stem cell transplanta-
tion may inﬂ  uence the post-transplant reconstitution of 
cellular immunity. Fattorossi and colleagues conducted a 
randomized, prospective clinical trial to test for differences 
in immune recovery among 39 patients with ovarian and 
breast cancer who received either G-CSF or GM-CSF after 
high dose myeloablative chemotherapy and autologous 
transplantation. At day 12, GM-CSF was more efﬁ  cient 
at up-regulating membrane molecules on phagocytic cells 
important for antibody-dependent cytotoxicity and for the 
uptake of immune complexes compared to treatment with 
G-CSF; and at day 80, a signiﬁ  cantly higher proportion of 
mitogen-stimulated T cells from GM-CSF-treated patients 
expressed interleukin-2 receptor, and a higher proportion 
of these T cells were actively proliferating (Fattorossi et al 
2001) . Recently, Gazitt and colleagues showed that among 
29 non-Hodgkin’s lymphoma (NHL) patients receiving 
cyclophosphamide plus GM-CSF, G-CSF or GM-CSF fol-
lowed by G-CSF for stem cell collection, patients mobilized 
with the GM-CSF containing regimens mobilized higher 
numbers of DC, and had a higher probability of survival 
compared to patients receiving G-CSF alone (median of 55 
months versus 15 months; p = 0.02). Of note, there was no Biologics: Targets & Therapy 2008:2(1) 18
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difference in the ratio of DC1:DC2 between CSF regimens. 
This ﬁ  nding supports the hypothesis that higher numbers of 
DCs in the graft might be associated with prolonged survival 
of NHL patients after autologous transplantation (Gazitt et al 
2006). Further studies in larger populations of patients are 
merited. More is known about the effects of G-CSF than the 
effects of GM-CSF on post-transplant immune reconstitution. 
Volpi and colleagues reported on the effects of G-CSF admin-
istration in the post-transplant setting among 43 patients 
with acute leukemia who received T-cell depleted peripheral 
blood progenitor cell transplants from HLA haplo-identical 
related donors, compared to a cohort of 36 patients with 
acute leukemia who did not receive G-CSF after transplanta-
tion. They found signiﬁ  cantly delayed recovery of Th1-type 
CD4+ T-cells (low IL-4 and IL-10, and high IL-12 receptor 
expression), a higher proportion of CD4+ T-cells with a Th2 
phenotype (high levels of IL-4 and IL-10, and low levels of 
IL-12 receptor expression), and impaired production of IL-12 
by dendritic cells, compared to patients who did not receive 
post-transplant G-CSF. T-cells from recipients of post-trans-
plant G-CSF had signiﬁ  cantly decreased in-vitro reactivity 
to fungal pathogens compared to T-cells from patients who 
did not receive post-transplant G-CSF. This ﬁ  nding suggests 
an increased susceptibility to opportunistic infections in the 
G-CSF treated cohort, given that Th1-responses are necessary 
for anti-fungal protection (Volpi et al 2001). The effect of 
G-CSF on post-transplant immune reconstitution appeared 
to be dependent on G-CSF’s inﬂ  uence on DC maturation and 
differentiation; given that administration of G-CSF following 
transplantation favored the appearance of IL-12-deﬁ  cient 
DC which polarize T-cells toward Th2 responses. Fagnoni 
reported a similar effect of post-transplant G-CSF in children 
(Fagnoni et al 2004). Ringden et al performed a retrospective 
analysis to determine the role of post-transplant treatment 
with G-CSF in patients with AML and acute lymphocytic 
leukemia (ALL) who received allogeneic BMT or peripheral 
blood grafts. They found that prophylactic, post-transplant 
treatment with G-CSF led to a higher risk of acute and 
chronic GVHD, higher transplant related mortality, and 
decreased overall survival and leukemia-free survival rates 
in patients who received BMT only. Post-transplant G-CSF 
led to faster engraftment of absolute neutrophil count but 
slower engraftment of platelets in transplant recipients 
irrespective of the type of graft (Ringden et al 2004). These 
findings suggest that post-transplant administration of 
G-CSF may cause an imbalance in dendritic cell content 
or function, resulting in impaired cellular immunity in the 
early post-transplant period. This may lead to an increase 
in the incidence of GVHD (Fagnoni et al 2004). Current 
guidelines support the use of colony stimulating factors 
for mobilization of autologous and allogeneic grafts and 
after peripheral blood progenitor cell transplantation in the 
autologous setting only (Smith et al 2006). Further studies 
are needed to support the addition of GM-CSF after allo-
geneic transplantation.
GM-CSF may improve antibody-
dependent cell-mediated 
cytotoxicity
The anti-CD20 antibody, rituximab, used alone or in com-
bination with chemotherapy, is an established treatment for 
non-Hodgkin’s lymphoma (NHL) (Cvetkovic and Perry 
2006). Augmenting the expression of CD20 antigen on the 
tumor cells may increase the cell kill and therefore increase 
the effectiveness of the antibody (Venugopal et al 2000). Pre-
liminary data suggest that GM-CSF can up-regulate the CD20 
expression on lymphoid B cells in vitro, but these results have 
not been reproducible in vitro nor in vivo (Venugopal et al 
2000; Chow et al 2001; Yagci et al 2005).
Venugopal and colleagues performed experiments on 
cells from patients with chronic lymphocytic leukemia 
(CLL) where CLL cells were cultured with cytokines and 
the expression of CD 20 on the surface of the CLL cells was 
measured before and after cytokine exposure. They found 
a statistically signiﬁ  cant up-regulation of CD20 antigen 
expression on CLL cells after culture with GM-CSF, IL-4, or 
TNF-alpha. Flow cytometry evaluation revealed an increase 
in ﬂ  uorescence intensity as well in the percentage of cells 
expressing the antigen (Venugopal et al 2000). This led to 
further studies which have revealed promising, but incon-
sistent results. Olivieri and his group showed the feasibility 
of rescuing patients with NHL relapsing after autologous 
transplantation with a regimen containing rituximab, CHOP 
chemotherapy and GM-CSF. They reported a 75% overall 
response rate (60% complete remission, and 15% partial 
response) among 20 patients with aggressive NHL who 
relapsed after autologous transplantation (Olivieri et al 2005). 
Rapoport and colleagues reported promising results utiliz-
ing post-transplant rituximab and GM-CSF after autologous 
transplantation among a group of patients with advanced 
NHL and Hodgkin’s disease (Rapoport et al 2002). However 
neither up-regulation of CD20 antigen, nor a change of the 
proportion of CD20 positive cells was observed after culture 
with GM-CSF in a study by Yagci et al (2005) on cells from 
18 patients with CLL.Biologics: Targets & Therapy 2008:2(1) 19
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GM-CSF may augment the graft 
versus leukemia effect of allogeneic 
transplantation
Relapse of acute leukemia after allogeneic transplanta-
tion remains a signiﬁ  cant therapeutic challenge, affecting 
approximately one third of all patients with acute leukemia 
who receive allogeneic transplantation as a curative therapy. 
Salvage post-transplant maneuvers have focused on utilization 
of second transplants, but these are limited to a minority (10% 
in most series) of ﬁ  t patients. Clinical and pre-clinical data 
has suggested a role for cytokine therapy in the induction of 
graft versus leukemia effects in the setting of post-transplant 
relapse (Slavin et al 1996; Cortes et al 1998; Boyer et al 2000; 
Mohty et al 2002; Kolb et al 2004; Li and Waller 2004). 
Improving the antigen-presenting capacity of leukemic blasts 
may lead to clinically-signiﬁ  cant anti-leukemic effects. The 
feasibility of generating DC-like leukemic antigen presenting 
cells upon treatment with cytokines, including GM-CSF has 
been demonstrated ( Santiago-Schwarz et al 1994; Mohty et al 
2002). The level of co-stimulatory molecule expression on 
leukemic blasts has been hypothesized to play a role in the 
capacity of leukemic blasts to present antigen to effector cells 
(Vereecque et al 2000; Whiteway et al 2003). A retrospec-
tive study at our institution reviewing the treatment of acute 
leukemia relapsed after allogeneic transplantation revealed 
promising results among a minority of patients treated with 
GM-CSF and interferon-alpha-2b (Arellano et al 2007). A 
prospective clinical trial at our center is currently investigating 
the feasibility and activity of a regimen utilizing the combina-
tion of GM-CSF and interferon-alpha-2b after cytoreduction 
to treat acute leukemia relapsed after allogeneic transplanta-
tion. Correlative studies will test the hypothesis that GM-CSF 
and interferon-alpha-2b act by up-regulating co-stimulatory 
molecules on leukemic blasts, and down-regulating regulatory 
T-cells leading to improved antigen presentation and durable 
graft versus leukemia effects (Figure 1).
GM-CSF for the treatment 
of solid tumors
Role of GM-CSF in the management 
of renal cell carcinoma
Renal cell carcinoma (RCC) is known to be an immunogenic 
tumor. Interferon-alpha (IFN-alpha) has been established 
as the standard treatment for metastatic RCC with response 
rates ranging between 10 and 20%. High dose interleukin-
2 has yielded similar results, but its use has been limited 
by significant toxicities (Coppin et al 2005). Previous 
observations have indicated that GM-CSF can potentiate 
the effect of IL-2 on T-cell activation (Masucci et al 1990; 
Groenewegen and de Gast 1999). Subsequently multiple trials 
have tested the activity of GM-CSF combinations for RCC 
with modest results. Table 1 summarizes activity and toxici-
ties of GM-CSF in the treatment of renal cell carcinoma. Verra 
and colleagues studied the effect of simultaneous administra-
tion of low dose IL-2, IFN-alpha and GM-CSF in metastatic 
RCC in a phase I study and, subsequently in a multicenter 
phase II study, showing tolerability and promising efﬁ  cacy 
with 19% overall responses (9% CR, 10% PR) (De Gast et al 
2000; Verra et al 2003). Recently, the same group conducted 
a phase I study of peri-operative low-dose IL-2, IFN-alpha, 
and GM-CSF in resectable RCC. In addition to determining 
the maximum tolerated dose of the cytokine combination in 
the peri-operative setting, the investigators studied the effects 
of the cytokines in the peripheral blood and at the tumor site. 
They found higher numbers of tumor-inﬁ  ltrating T-cells and 
mature DC1 in tumors resected from patients who received 
peri-operative cytokines, compared to a control group of 
tumors resected from non-cytokine treated patients (Verra 
et al 2005). The advent of targeted therapy for RCC has 
marked a new paradigm in the treatment of this tumor (Motzer 
and Bukowski 2006), and further studies may ﬁ  nd a role for 
combining cytokines with the newer targeted agents.
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Figure 1 GM-CSF and IFN may upregulate co-stimulatory molecule expression on 
leukemic blasts leading to stimulation of cytotoxic T-cells and a GVL effect.
Abbreviations: APC, antigen presenting cells; GVL, graft versus leukemia; GM-CSF, 
granulocyte-macrophage-colony-stimulating factor; IFN, interferon; CTL, cytotoxic 
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Table 1 Recent trials using GM-CSF in patients with renal cell carcinoma
Author Population Immune therapy Dose of GM-CSF Outcomes Toxicities (most 
common)
Correale et al 2005 19 Metastatic RCC IL-2 0.5 MIU BID
SQ D 6–15
150 μg /day SQ D 1–5 PR: 4/19
SD: 11/19
mTTP = 9 months 
2 year OS 42%
3 year OS 26%
Bone pain, asthenia, 
and fever
Verra et al 2003 59 Progressive RCC IL-2: 4 MIU/m2 SQ
INF-α :5MIU SQ
× 12 days every 3 wks
2.5 μg/kg SQ
D 1–12
CR: 5/59
PR: 6/59 
mOS: 9.5 mos.
Flu-like symptoms, 
transient LFT eleva-
tions
Lissoni et al 2003 25 Metastatic RCC IL-2: 6 MIU/day SQ 
6 D/wk × 4 wks
2 cycles (21-day 
intervals)
Maintenance: 6 days/
month until progres-
sion
13 patients also 
received GM-CSF 
0.3 μg /kg D 1–3 each 
week of Il-2 
IL-2 alone
PR: 3/13
SD: 8/13
IL-2 + GM
PR: 3/12
SD: 6/12
More asthenia 
occurred in the IL-2 + 
GM group
Smith et al 2003 21 (13 with metastatic 
RCC)
IL-2: 72,000 IU/kg
TID × on D 2–6 and
D16–20 ± GM-CSF
125 or 250 μg /m2/day 
SQ D 1–7 and
D 15–21
No PR or CR
SD: 4/13 with RCC
Grade 3 confusion in 
4 pts (3 on IL-2 alone)
Schmidinger et al 2001 55 Metastatic RCC IL-2: 4.5 MU day 1–4 
wks. 3 and 6
INF-γ: 100 μg TIW 
wks 1 and 4
400 μg SQ D 1–5 
weeks 2 and 5
CR: 1/53,.
PR: 4/53
SD: 14/53
mOS: 12 mos
No toxicities greater 
than grade 2
Westermann et al 2001 10 Stage IV RCC
Pilot study
IL-2: 4 MU/m2 SQ 
and INF-α: 5 MIU/m2 
SQ multiple dosing 
schedules
5 μg /kg SQ
D 1 + 4 week 1
D 1, 3, 5 week 2
D 1, 3, 5 weeks 3–5
D 1, 3, 5 weeks 7–9
PR 2/10 
1/10 mixed response
One grade 3 fever
No other grade 3–4 
toxicities
Tate et al 2001 13 Metastatic RCC, 
Phase I
IL-6 1, 5, or 10 μg/kg/
day D 1–14
3 μg /kg/day
D1–14
No responses DLT: thrombocytosis 
and hyperbilirubinemia
De Gast et al 2000 18
11 RCC
7 melanoma
Phase I
IL-2: 1, 4, or 8 MIU/m2, 
and INF-α: 5 MIU SQ 
× 12 days every 3 wks
2.5 or 5 μg /kg/day SQ CR: 3/11
SD: 5/11
DLT: fever with chills, 
hypotension, ﬂ  uid 
retention
Ryan et al 2000 20 Metastatic RCC IL-2: 11 MIU SQ 
D1–4 weekly
INF-α: 10 MIU SQ
2 days/week
c-RA 1 mg/kg daily 
orally for 4 weeks
1.25 μg /day SQ 
D 1–14
PR: 1
SD: 3
1-year survival rate: 
48%
Grade 3 fever, fatigue, 
anorexia mucositis, 
and dermatitis
One on-study death
Hotton et al 2000 16 pts with RCC and 
pulmonary metastases
IL-2: 1.5, 2.25, or 4.5 
MIU/m2/day 96 h CIV
D 1–4, 8–11, and 
15–18
1.25, 2.25, or 2.5 
g/kg/day SQ D 8–19
14 evaluable
0/14 had  50% 
shrinkage of total 
tumor burden nor 
reduction in pulmo-
nary metastases
Grade 3–4 toxicities:
lymphopenia, throm-
bocytopenia, elevated 
PT, thrombosis, hypo-
tension, hypocalcemia, 
hyperglycemia, pain, 
constipation
Grade 5: neurologic
Abbreviations: c-RA, cis-retinoic acid; CR, complete response; D, days; INF-α, interferon alpha; INF-γ, interferon gamma; OR, overall response; PR, partial response; pt, patient; 
SQ, subcutaneous; IL-2, interleukin 2; PR, partial response; mOS, median overall survival; LFT, liver function test; wks, weeks; mTTP, median time to progression; CIV, continu-
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Role of GM-CSF in the management 
of malignant melanoma
Unresectable melanoma carries a poor prognosis with lim-
ited options for treatment (Parmiani et al 2007). GM-CSF 
has been shown to induce cytotoxic T-cells and activated 
DC at tumor sites and draining lymph nodes (Parmiani et al 
2007). The use of GM-CSF in combination with IL-2 or 
IFN-alpha has yielded promising results, but is associated 
with signiﬁ  cant systemic toxicity. Table 2 summarizes activ-
ity and toxicities of GM-CSF-containing regimens in the 
treatment of malignant melanoma. Delivery of therapy into 
local sites of disease may circumvent systemic toxicity and 
is the subject of current investigation.
GM-CSF and cancer vaccine 
development
Addressing questions pertaining to the choice of vector, the 
speciﬁ  city of the antigen, and the choice of co-stimulatory 
molecules is crucial to the optimal development of cancer 
vaccines. Tumor-associated antigens from tumor cells (both 
autologous and allogeneic), proteins, peptides, and nucleic 
acid have been used as immunogens. Genetically modiﬁ  ed 
allogeneic tumor cells as well as recombinant viruses or 
bacterial genes have been utilized as vectors. Pre-existing 
immunity to the vector itself has limited the use of vaccines 
based on viral vectors (Rosenberg et al 1998). Vaccination 
in the absence of the co-stimulatory signals necessary to 
break tolerance can lead to anergy. Therefore, some vectors 
have been designed to express not only tumor-associated 
antigens, but also, co-stimulatory molecules and cytokines. 
Dranoff et al (1993) introduced GM-CSF as an important 
adjuvant in cancer vaccine trials, based on his observations 
that irradiated tumor cells expressing murine GM-CSF could 
stimulate potent, long-lasting, and tumor-speciﬁ  c immunity. 
In order to circumvent systemic toxicity and to increase 
immune responses, injection into the local tumor environ-
ment has been proposed. Hersch and colleagues used intra-
tumor injection of HLA-B7/beta2-microglobulin genes as 
plasmid DNA in lipid into patients with malignant melanoma. 
In a phase I trial setting, they reported a 36% response at the 
locally injected tumor and a 19% systemic anti-tumor response 
(Hersh and Stopeck 1997).Vaccine trials utilizing GM-CSF 
or engineering tumor cells to secrete GM-CSF showed 
encouraging results in the treatment of solid tumors including: 
malignant melanoma, breast carcinoma, pancreatic cancer, 
renal cell carcinoma, non-small cell carcinoma of the lung 
and prostate cancer (Schmidt et al 1997; Simons et al 1997; 
Hung et al 1998; Soiffer et al 1998; Disis et al 1999; 
Gaudernack and Gjertsen 1999; Leong et al 1999). Cassaday 
and colleagues performed a phase I study of immunization 
using particle-mediated epidermal delivery (PMED) of genes 
for gp100 and GM-CSF into uninvolved skin of melanoma 
patients. Two groups of 6 patients each were treated; group 1 
received PMED with cDNA for gp100, and group 2 received 
PMED with cDNA for GM-CSF followed by PMED for 
gp100 at the same site. Biopsies were obtained and evaluated 
to assess transgene expression, gold-bead penetration, and 
dendritic cell inﬁ  ltration. Exploratory studies included ﬂ  ow 
cytometric analyses of peripheral blood lymphocytes and 
evaluation of delayed-type hypersensitivity to gp100 peptide 
in HLA-A2 + patients. Local toxicity in both groups was mild 
and resolved within 2 weeks. No vaccine-related systemic 
toxicity was reported, including no induction of pathologic 
auto-antibodies. GM-CSF transgene expression in vaccinated 
skin sites was detected. GM-CSF and gp100 PMED yielded 
a greater inﬁ  ltration of DC into vaccine sites than did gp100 
PMED alone. Immunologic monitoring suggested modest 
activation of an anti-melanoma response (Cassaday et al 
2007). This study demonstrated tolerability and induction 
of anti-melanoma immune responses with a local approach. 
Additional investigation utilizing this technique is warranted. 
Bendandi and colleagues tested the hypothesis that immune 
therapy is more effective in the setting of minimal residual 
disease (MRD). They documented clearance of the t(14,18) 
translocation by PCR from the peripheral circulation in 8 of 
11 patients with lymphoma and MRD, after administration 
of a GM-CSF containing vaccine (Bendandi et al 1999). 
Currently our center participates in a multi-institutional trial 
of vaccine therapy for AML after remission induction. GM-
CSF may enhance antigen presentation by recruiting DC to 
the (vaccine) site where antigen is taken up, processed, and 
presented to T-cells in draining lymph nodes, generating 
systemic tumor-speciﬁ  c responses (Borrello and Pardoll 
2002).
Cell-mediated vaccines: role 
of dendritic cells
DC are ideal candidates for use in vaccination, owing to 
their role in antigen presentation. DC can be isolated from 
the peripheral circulation by FACS sorting or magnetic bead 
isolation, or can be generated in large quantities ex-vivo 
from peripheral blood progenitors in media supplemented 
with cytokines, including GM-CSF (Berthier et al 2000). 
These DC may then be matured with cytokine culture 
prior to loading with antigen. They have yielded promising Biologics: Targets & Therapy 2008:2(1) 22
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Table 2 GM-CSF-containing regimens in patients with malignant melanoma
Author Population Concurrent 
therapy
Dose of GM-CSF Outcomes Toxicities (most 
common)
Lutzky et al 2003 11 Thalidomide: intra-
patient dose escalation 
50–400 μg PO daily
125 μg/m2 SQ daily × 
14 days
3 alive without recur-
rent disease
Most common: fatigue, 
dizziness, somnolence, 
constipation
Weber et al 2005 31 Temozolamide: days 
1–5
INFα-2b: days 6–17 
IL-2: days 6–17
125 μg/m2 SQ days 
6–17
CR: 4 
PR: 4 
SD: 7 
mOS: 15.9 mos
SAEs in 7 patients
Most common toxic-
ity: ﬂ  u-like symptoms
De Gast et al 2003 74 Temozolamide: days 
1–5
INFα-2b: days 6–17 
IL-2: days 6–17 
Repeated every 
22 days in stable/
responding pts
2.5 μg/kg SQ days 
6–17
CR: 4 s
PR: 19 
SD: 13 
mOS: 252 day
DLT: thrombocyto-
penia
Grade 3–4 lymphope-
nia was observed
All patients developed 
ﬂ  u-like syndrome
Groenewegen and de 
Gast 1999; Groenewe-
gen et al 2002
32 DTIC: day 1 
IL-2: days 6–17 
INFα-2b: days 6–17
2.5 μg/kg SQ days 
2–12
CR: 4 
PR: 6 
mOS: 8 mos
Treatment was well 
tolerated
Janik et al 2001 28 Topotecan: 1.5 mg/m2 
daily x 5 days 
Cycle repeated every 
21 days
250 μg/m2 SQ QD 
post CHT 
250 μg/m2 SQ BID × 
5 D prior to CHT; or 
none
CR: 0 
PR: 1
Treatment was well 
tolerated
Ravaud et al 2001 32 A: None 
B: DTIC 800 mg/m2 D 
1 21-day cycles 
Cross-over from A 
to B allowed for non-
response/progression
A: 5 μg/kg BID SQ × 
14 D 
 B: 5 μg/kg BID SQ 
D2-19, 
21-day cycles
Best response was SD: 
A: 0 
B: 3 
OS 
A: 6.3 months 
B: 7.3 months
Dose alteration due 
to toxicity in 20% A 
and 4.7% B
Grade 3 or 4 toxicity 
occurred in 40% A 
and 76.5% B
Gajewski and Flickinger 
2000
7 Cisplatin, DTIC: D1 
IL-2: D 8–14 
INF-α: D 8,10,12,14 
28 day cycles
5 μg/kg SQ D 2–7 CR: 1 
PR: 1 
MR: 2
Treatment was well 
tolerated
Gibbs et al 2000  72 Temozolamide: D1–5
Cisplatin: D 1–3 
IL-2: D 1–4 
INF-α: D 1–5 
28-day cycles
250 μg SQ days 6–25 CR: 1 
PR: 11 
mOS: 11 mos
Signiﬁ  cant toxicity 
with grade 2 and 4 
thrombocytopenia and 
renal impairment
Vaughan et al 2000 19 Cisplatin: D 1–3 
DTIC: D 1–3 
Tamoxifen: daily 
IL-2: D 6–10, 17–21 
INFα-2b: days 6–10 
and 17–21 
28-day cycles
450 μg/m2 SQ D 
4,5,15,16 or 
450 μg /m2 SQ 
D 4,5,15,16 and 225 
μg/m2 SQ D 6–10, 
17–21 or 
450 μg /m2 SQ 
D 4–10, 15–21
OR: 6 
CR: 2 
mOS: 6.2 mos.
Grade 3–4 toxicities:
bone marrow sup-
pression, hypoten-
sion, pulmonary 
edema, confusion, 
and increased serum 
creatinine
Schachter et al 1998 40 INF-α: days 1,3,5 
Carmustine: day 8 
Cisplatin: days 8–10 
DTIC: days 8–10 
Tamoxifen: daily 
21-day cycles
20 μg/m2/day 
SQ × 7 days following 
chemotherapy
CR: 9 
PR: 11 
Survival beneﬁ  t in 
responders: 22 mos. vs 
8 mos.(p = 0.0001)
Treatment was well 
tolerated
Abbreviations: bid, twice daily; TIW, 3 times weekly; DTIC, dacarbazine; INF-α, interferon alpha; IL-2, interleukin 2; PD, progressive disease; PO, orally; PR, partial response; 
pt, patient; OR, overall response; mOS, median overall survival; SQ, subcutaneously; LFT, liver function test; wks, weeks; CHT, chemotherapy; D, days; DLT, dose-limiting toxicity; 
SAEs, serious adverse events.Biologics: Targets & Therapy 2008:2(1) 23
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results and continue to be tested in the treatment of solid 
and hematological malignancies. Results from phase 1 and 
2 clinical trials indicate that tumor-peptide loaded DC can 
induce clinically signiﬁ  cant immune responses in patients 
with lymphoma and melanoma (Hsu et al 1996; Hersey et al 
2004). Antigen-loaded DC as cancer vaccines have been 
limited by uncertainty regarding the best DC subtype to use, 
the optimal maturation status of the DC, the best site of admin-
istration (sub-cutaneous, intra-venous, or intra-nodal) and the 
optimal schedule of administration. More research is needed 
in order to answer these questions and deﬁ  ne the optimal use 
of GM-CSF as an adjuvant in cell-mediated vaccines.
Future directions
Pre-clinical and clinical data support the role of GM-CSF as an 
immune adjuvant in the treatment of malignant solid and liquid 
tumors, but the challenge remains to devise combinations of 
cytotoxic and cytokine therapy which are synergistic in break-
ing immune tolerance, enhancing antigen presentation and 
up-regulating anti-tumor T-cell responses. Local production of 
GM-CSF by tumors in the setting of tumor-speciﬁ  c vaccina-
tion has shown promise in the induction of anti-tumor immune 
responses. However, the laboratory correlates of response; 
such as, the lymphocytic and inﬂ  ammatory inﬁ  ltrates that 
develop at the site of vaccination and cytokine injection, do not 
reproducibly correlate with improved clinical outcomes, and 
well designed translational studies are needed to better deﬁ  ne 
the anti-tumor activity of GM-CSF and other cytokines. Vac-
cines and cytokine therapies are attractive for use in patients 
who cannot tolerate further cytotoxic chemotherapy, owing 
to their relatively low toxicity, and in patients whose tumors 
are in a minimal residual disease state.
Table 3 Clinical trials using GM-CSF transduced tumor cells as vaccines
Authors Tumor type Clinical results
Slingluff et al 2003
.
Melanoma
Randomized comparison of multipeptide vac-
cine either in emulsion with GM-CSF or pulsed 
on monocytoid DCs
–   Overall immune responses, including T-cell 
responses were superior in the GM-CSF arm, 
compared to the DC arm
–   Helper T-cell responses were detected and 
correlated with T-cell reactivity to the mela-
noma peptides
–   2 PR in the GM-CSF arm, 1 in the DC arm. 
-2 SD in the GM-CSF arm and 1 in the DC arm
–   mOS:14.8 months for patients in the GM-
CSF arm and 6.2 months for the DC arm.
Nelson et al 2000 Renal cell carcinoma –   Increase in DTH response against autologous 
tumor cells
– 1 PR
Simons et al 1999; Simons and Sacks 2006 Prostate cancer – Increase in DTH response
–   Induction of tumor speciﬁ  c T-cell and B-cell 
responses
Kusumoto et al 2001 Melanoma – Increase in DTH response
–   Increase in melanoma speciﬁ  c CTLs in most 
patients
Soiffer et al 1998; Soiffer et al 2003 Melanoma – Increase in DTH response
– Eosinophilia
– TILs highly cytotoxic
– 1 CR, 1PR, 1MR, 3 minor responses
Salgia et al 2003 Non-small cell lung Cancer – Increase in DTH response
–  T-cell and plasma cell inﬁ  ltration of metastatic 
sites
– 5 SD, 1 mixed response
Jaffee et al 2001 Pancreatic cancer – Increase in DTH response
– Increased systemic GM-CSF levels
–   2/5 patients receiving highest cell dose  25 
months in CR
Abbreviations: DTH, delayed type hypersensitivity; PR, partial response; CTLs, cytotoxic T lymphocytes; TILs, tumor inﬁ  ltrating lymphocytes; MR, minor response; SD, stable 
disease; mOS, median overall survival; CR, complete response.Biologics: Targets & Therapy 2008:2(1) 24
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The success of cytokine therapy will likely depend upon 
deﬁ  ning the most favorable combination of cytokines, the 
optimal site and route of administration, reaching a MRD 
status prior to cytokine therapy, and development of surrogate 
endpoints of anti-tumor activity that can be used to design 
subsequent clinical trials.
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